Gregg Sherman, MD
Chief Medical Officer, NACE
Kilbride Associates Healthcare Communications
San Francisco, CA
Franck Rahaghi, MD, MHS, FCCP
Director of Advanced Lung Disease Clinic
Director, Pulmonary Hypertension Clinic
Head of Alpha-1 Foundation Clinical Resource Center
Chairman, Dept. of Pulmonary and Critical Care
Cleveland Clinic Florida
Kevin Flaherty, MD, MS
Professor in Pulmonary and
Critical Care Medicine
University of Michigan Health System
Ann Arbor, MI
David J. Lederer, MD, MS
Associate Professor of Medicine &
Co-Director, Interstitial Lung Disease
Columbia University Medical Center
New York, NY
Fernando J. Martinez, MD, MS
Chief, Division of Pulmonary and Critical Care Medicine
Bruce Webster Professor of Medicine
Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medical College
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, NY
Arunabh Talwar, MD, FCCP
Director, Pulmonary Hypertension and Advanced Lung Disease Program
North Shore University Hospital, Manhasset, New York
Professor Of Medicine
Hofstra Northwell School of Medicine
||Demystifying A1AT Deficiency and COPD: A Practical Guidance for Clinicians
||Aug 18 2017
||Aug 17 2018
||Primary Care Providers
||1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.25 pharmacology hour(s)
Welcome to the National Association for Continuing Education webcast from the NACE Emerging Challenges in Primary Care 2017 conference.
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease characterized by airflow limitation that is progressive and associated with an enhanced chronic inflammatory response in the lung to noxious particles or gases. Deficiency of alpha-1 antitrypsin (AAT) is the best-studied genetic risk factor for COPD and one of the most common genetic disorders among Caucasians. The availability of specific therapy for AATD makes it possible to improve outcomes, but however, AATD is underrecognized and undertreated. This program will discuss diagnosis and treatment options for patients with COPD and AATD, with the most recent recommendations from the GOLD 2017 report.
This webcast was recorded live and is being used with the permission of the presenters.
After completing this program participants should be able to:
- Discuss the pathophysiology of Alpha-1 Antitrypsin Deficiency (AATD).
- Utilize appropriate screening for AATD.
- Incorporate AATD testing into routine chronic obstructive pulmonary disease (COPD) management algorithm.
- Discuss treatment options for AATD and latest GOLD guideline recommendations.
How To Obtain Your CME Certificate 1. Register for the course at www.naceonline.com.
2. View the content.
3. Complete and submit the post-test and evaluation.
4. A minimum passing score of 80% must be earned on the post-test in order to complete the CME
5. Print your CME certificate.
National Association for Continuing Education
|Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.
National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education(which includes 0.25 pharmacology hours).
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.
Franck Rahaghi, MD, MHS, FCCP serves as a Consultant/Speaker/Researcher for Boehringer Ingleheim, Genentech, Merck, CSL Behring, Shire and Grifols.
Kevin Flaherty, MD, MS serves as a consultant for Boehringer Ingleheim and Genentech. Dr. Flaherty also serves on the advisory board for Fibrogen.
David J. Lederer, MD, MS serves on the scientific advisory board committee for Boehringer-Ingelheim, Genentech, Global Blood Therapeautics, Roche, Fibrogen, Veracyte, Patara, and Philips Repsironics.
Fernando Martinez, MD, MS serves on the steering committee for Afferent, AstraZeneca, Bayer, Boehringer-Ingelheim, Gilead, GSK, and Veracytes. Dr. Martinez also serves on the advisory board for Adept, AZ, BI, ProTerrix Bio, Concert, Genentech, GSK, Novartis, Patara, Pearl, and Theravance. Dr. Martinez has done CME Presentations and served as a speaker for AZ, BI, Columbia University, GSK, Integritas, Methodist Hospital, Mitler, NYU, NACE, Peer View, Potomac, Prime, and the Puerto Rican Respiratory Society. Additionally, Dr. Martinez has served on the DSMB for Chiesl, UpToDate, WebMD, Biogen, and GSK.
Arunabh Talwar, MD, FCCP serves as a speaker for Boehringer Ingleheim.
Gregg Sherman, MD, Course Director, has no relationships to disclose.
Josh Kilbridge, Medical Writer, has no relationships to disclose.
Harvey C. Parker, Ph.D., Activity Planning Committee, has no relationships to disclose.
Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.
Alan Goodstat, LCSW, Activity Planning Committee, has no relationships to disclose.
Cheryl C. Kay, Activity Planning Committee, has no relationships to disclose.
This educational activity is supported by an educational grant from Grifols.